Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование для оценки эффективности и безопасности JNJ-77242113 по сравнению с плацебо и Ustekinumab у участников с псориазом от умеренной до тяжелой. (ICONIC-ASCEND)

2 ноября 2026 г. обновлено: Janssen Research & Development, LLC

Фаза 3 Многоцентровое рандомизированное, двойное слепое, плацебо-контролируемое и активное исследование, контролируемое компаратором, для оценки эффективности и безопасности JNJ-77242113 для лечения участников с псориасом из умеренной до тяжелой доры от умеренной до тяжелой доски для получения деликатеса.

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Обзор исследования

Тип исследования

Интервенционный

Регистрация (Действительный)

752

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Clayton, Австралия, 3168
        • Monash Medical Centre
      • Coorparoo, Австралия, 4151
        • Cornerstone Dermatology
      • Greenslopes, Австралия, 4120
        • Veracity Clinical Research
      • Kogarah, Австралия, 2217
        • Premier Specialists
      • Melbourne, Австралия, 3004
        • The Alfred Hospital
      • Melbourne, Австралия, 3050
        • Royal Melbourne Hospital
      • Mitcham, Австралия, 3132
        • ISHI dermatology
      • Westmead, Австралия, 2145
        • Westmead Hospital
      • Feldkirch, Австрия, 6800
        • LKH Feldkirch
      • Linz, Австрия, 4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten, Австрия, 3100
        • Universtitatsklinikum St Poelten
      • Vienna, Австрия, 1090
        • Allgemeines Krankenhaus der Stadt Wien
      • Barrio Gral Paz Cba Capital, Аргентина, X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires, Аргентина, B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires, Аргентина, C1417EYG
        • Mindout Research
      • Buenos Aires, Аргентина, C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA, Аргентина, C1061AAS
        • CIPREC
      • CABA, Аргентина, C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA, Аргентина, C1055AAO
        • Buenos Aires Skin
      • CABA, Аргентина, C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA, Аргентина, C1128
        • Mautalen Salud e Investigacion
      • Caba, Аргентина, C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario, Аргентина, S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando, Аргентина, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, Аргентина, T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Brussels, Бельгия, 1090
        • UZ Brussel
      • Ghent, Бельгия, 9000
        • Ghent University Hospital
      • Ghent, Бельгия, 9000
        • AZ St. Lucas
      • Leuven, Бельгия, 3000
        • Universitair Ziekenhuis Leuven
      • Liège, Бельгия, 4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem, Бельгия, 9990
        • Dermatologie Maldegem
      • Budapest, Венгрия, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, Венгрия, 1152
        • Uno Medical Trials Ltd.
      • Debrecen, Венгрия, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen, Венгрия, 4031
        • Derma-B Kft
      • Gyula, Венгрия, 5700
        • Synexus Magyarorszag Kft
      • Gyöngyös, Венгрия, 3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely, Венгрия, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár, Венгрия, 7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét, Венгрия, 6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok, Венгрия, 5000
        • Allergo-Derm Bakos Kft.
      • Veszprém, Венгрия, 8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
      • Augsburg, Германия, 86179
        • Klinikum Augsburg
      • Bad Bentheim, Германия, 48455
        • Fachklinik Bad Bentheim
      • Berlin, Германия, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn, Германия, 53127
        • Universitatsklinikum Bonn
      • Bramsche, Германия, 49565
        • Studienzentrum an der Hase GbR
      • Darmstadt, Германия, 64283
        • Rosenpark Research GmbH
      • Dresden, Германия, 01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen, Германия, 88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel, Германия, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau, Германия, 89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow, Германия, 15831
        • Dermatologie Mahlow
      • Mainz, Германия, 55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster, Германия, 48149
        • Universitaetsklinikum Muenster
      • Witten, Германия, 58453
        • Hautarztpraxis
      • Aalborg, Дания, 9100
        • Aalborg Sygehus Syd
      • Aarhus, Дания, 8200
        • Aarhus University Hospital
      • Hellerup, Дания, 2900
        • Gentofte Hospital
      • København NV, Дания, 2400
        • Bispebjerg Hospital
      • Odense, Дания, 5000
        • Odense University Hospital
      • Roskilde, Дания, 4000
        • Sjællands University hospital
      • Alicante, Испания, 03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo, Испания, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, Испания, 08036
        • Hosp. Clinic de Barcelona
      • Granada, Испания, 18016
        • Hosp. Univ. San Cecilio
      • Madrid, Испания, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Испания, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Испания, 28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises, Испания, 46940
        • Hosp. de Manises
      • Santiago Compostela, Испания, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, Испания, 41009
        • Hosp. Virgen Macarena
      • Seville, Испания, 41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia, Испания, 46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa, Испания, 03570
        • Hosp. de La Marina Baixa
      • Zaragoza, Испания, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza, Испания, 50009
        • Hosp. Univ. Miguel Servet
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Канада, A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax, Ontario, Канада, L1S7K8
        • CCA Medical Research Corporation
      • Barrie, Ontario, Канада, L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton, Ontario, Канада, L8N 1Y2
        • Dermatrials Research
      • London, Ontario, Канада, N6A 5R9
        • Lovegrove Dermatology
      • Markham, Ontario, Канада, L3P 1X3
        • Lynderm Research Inc.
      • Waterloo, Ontario, Канада, N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal, Quebec, Канада, H2X 2V1
        • Innovaderm Research Inc.
      • Québec, Quebec, Канада, G1W 4R4
        • The Centre de recherche Saint-Louis
      • Bialystok, Польша, 15 375
        • Specderm Poznanska sp j
      • Bialystok, Польша, 15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag, Польша, 82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice, Польша, 40 568
        • Care Clinic Sp z o o
      • Krakow, Польша, 30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz, Польша, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn, Польша, 10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan, Польша, 60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice, Польша, 96 100
        • Velocity Nova Sp z o o
      • Warsaw, Польша, 02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw, Польша, 02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw, Польша, 52 416
        • Centrum Medyczne Oporow
      • Wroclaw, Польша, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Guimarães, Португалия, 4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria, Португалия, 2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon, Португалия, 1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, Португалия, 1998 018
        • Hosp. Cuf Descobertas
      • Porto, Португалия, 4099 001
        • Ulssa Hosp. Santo Antonio
      • Dudley, Соединенное Королевство, DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow, Соединенное Королевство, HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn, Соединенное Королевство, PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London, Соединенное Королевство, SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading, Соединенное Королевство, RG1 5AN
        • Royal Berkshire Hospital
      • Salford, Соединенное Королевство, M6 8HD
        • Salford Royal Hospital
      • Southampton, Соединенное Королевство, So166yd
        • University Hospital Southampton
      • Wakefield, Соединенное Королевство, WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35244
        • Cahaba Research Inc
    • California
      • Encinitas, California, Соединенные Штаты, 92024
        • California Dermatology & Clinical Research Institute
      • Encino, California, Соединенные Штаты, 91436
        • T Joseph Raoof Md Inc
      • Fountain Valley, California, Соединенные Штаты, 92708
        • First OC Dermatology
      • Oceanside, California, Соединенные Штаты, 92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin, California, Соединенные Штаты, 95765
        • NorCal Clinical Research
      • Sacramento, California, Соединенные Штаты, 95815
        • Integrative Skin Science and Research
      • San Diego, California, Соединенные Штаты, 92103
        • MedDerm Associates
      • Santa Ana, California, Соединенные Штаты, 92701
        • Southern California Dermatology
      • Sylmar, California, Соединенные Штаты, 91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington, Connecticut, Соединенные Штаты, 06030
        • University of Conn Health Center
    • Florida
      • Miami, Florida, Соединенные Штаты, 33155
        • Bioclinical Research Alliance Inc.
      • Miami, Florida, Соединенные Штаты, 33126
        • Driven Research LLC
      • Ocala, Florida, Соединенные Штаты, 34470
        • Renstar Medical Research
      • Tampa, Florida, Соединенные Штаты, 33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta, Georgia, Соединенные Штаты, 30022
        • Hamilton Research LLC
    • Illinois
      • Skokie, Illinois, Соединенные Штаты, 60076
        • Northshore Medical Group
    • Indiana
      • Plainfield, Indiana, Соединенные Штаты, 46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City, Iowa, Соединенные Штаты, 52242
        • University of Iowa
    • Kentucky
      • Bowling Green, Kentucky, Соединенные Штаты, 42104
        • Equity Medical
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02111
        • Tufts Medical Center
      • Brighton, Massachusetts, Соединенные Штаты, 02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia, Michigan, Соединенные Штаты, 49316
        • The Derm Institute of West Michigan
      • Detroit, Michigan, Соединенные Штаты, 48202
        • Henry Ford Hospital
      • Fort Gratiot, Michigan, Соединенные Штаты, 48059
        • Hamzavi Dermatology
      • Troy, Michigan, Соединенные Штаты, 48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton, Minnesota, Соединенные Штаты, 55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville, Missouri, Соединенные Штаты, 63501
        • Cleaver Dermatology
      • Saint Joseph, Missouri, Соединенные Штаты, 64506
        • MediSearch Clinical Trials
    • New York
      • New York, New York, Соединенные Штаты, 10075
        • Sadick Research Group
      • New York, New York, Соединенные Штаты, 10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington, North Carolina, Соединенные Штаты, 28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman, Ohio, Соединенные Штаты, 44512
        • Optima Research
      • Mayfield Heights, Ohio, Соединенные Штаты, 44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland, Oregon, Соединенные Штаты, 97210
        • Oregon Dermatology and Research Center
      • Portland, Oregon, Соединенные Штаты, 97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Соединенные Штаты, 19114
        • Clinical Research Philadelphia
      • Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City, South Dakota, Соединенные Штаты, 57702
        • Health Concepts
    • Tennessee
      • Nashville, Tennessee, Соединенные Штаты, 37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington, Texas, Соединенные Штаты, 76011
        • Arlington Research Center, Inc.
      • Dallas, Texas, Соединенные Штаты, 75231
        • Modern Research Associates PLLC
      • Houston, Texas, Соединенные Штаты, 77004
        • Center for Clinical Studies 1
      • San Antonio, Texas, Соединенные Штаты, 78218
        • Texas Dermatology and Laser Specialists
      • San Antonio, Texas, Соединенные Штаты, 78213
        • Progressive Clinical Research
      • Webster, Texas, Соединенные Штаты, 77598
        • Center for Clinical Studies
    • Utah
      • West Valley City, Utah, Соединенные Штаты, 84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek, Washington, Соединенные Штаты, 98012
        • Frontier Derm Partners CRO, LLC

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

12 лет и старше (Ребенок, Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Плацебо Компаратор: Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

Активный компаратор: Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

Другие имена:
  • СТЕЛАРА
  • НКТО 1275

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Временное ограничение: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Временное ограничение: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Временное ограничение: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Временное ограничение: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Временное ограничение: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Временное ограничение: Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Временное ограничение: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Временное ограничение: Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Временное ограничение: Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Временное ограничение: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Временное ограничение: Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Временное ограничение: Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Временное ограничение: Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Временное ограничение: Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Временное ограничение: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Временное ограничение: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Временное ограничение: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Временное ограничение: Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Временное ограничение: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Временное ограничение: Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Временное ограничение: Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Временное ограничение: Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Временное ограничение: Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Временное ограничение: Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Временное ограничение: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Временное ограничение: Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

15 апреля 2025 г.

Первичное завершение (Действительный)

17 ноября 2025 г.

Завершение исследования (Оцененный)

20 августа 2027 г.

Даты регистрации исследования

Первый отправленный

11 апреля 2025 г.

Впервые представлено, что соответствует критериям контроля качества

11 апреля 2025 г.

Первый опубликованный (Действительный)

18 апреля 2025 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • 77242113PSO3006
  • 77242113PSO3006 (Другой идентификатор: Janssen Research & Development, LLC)
  • 2024-515706-77-00 (Идентификатор реестра: EUCT number)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

продукт, произведенный в США и экспортированный из США.

Да

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться